JAK protein kinase inhibitors

Drug News and Perspectives

Volumn 18, Issue 5, 2005, Pages 305-310

  Thompson, James E ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 HYDROXYANILINO) 6,7 DIMETHOXYQUINAZOLINE; 4 [N [1 (2 CYANO 1 OXOETHYL) 4 METHYL 3 PIPERIDINYL] N METHYLAMINO] PYRROLO[2,3 D]PYRIMIDINE; 4 [N [1 (2 CYANO 1 OXOETHYL) 4 METHYL 3 PIPERIDINYL] N METHYLAMINO]PYRROLO[2,3 D]PYRIMIDINE; DIPYRONE; IMATINIB; INTERLEUKIN 2; JANUS KINASE; JANUS KINASE 1; JANUS KINASE 2; JANUS KINASE 3; JANUS KINASE INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; NC 1153; PHYTOHEMAGGLUTININ; PNU 158804; PREDNISOLONE; STAT PROTEIN; UNCLASSIFIED DRUG;

CELL ACTIVATION; CLINICAL TRIAL; ENZYME ACTIVITY; ENZYME INHIBITION; GRAFT REJECTION; HUMAN; LEUKEMIA; NONHUMAN; ORGAN TRANSPLANTATION; PROPHYLAXIS; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; X RAY CRYSTALLOGRAPHY;

ANIMALS; DRUG DESIGN; ENZYME INHIBITORS; FORECASTING; GENE EXPRESSION REGULATION; HUMANS; JANUS KINASE 1; JANUS KINASE 2; JANUS KINASE 3; MANNICH BASES; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; PYRIMIDINES; PYRROLES; QUINAZOLINES; SIGNAL TRANSDUCTION; TYK2 KINASE;

EID: 27144452311     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: 10.1358/dnp.2005.18.5.904198     Document Type: Review

References (70)

1. Leonard, WJ. Role of Jak kinases and STATs in cytokine signal transduction Int J Hematol 2001, 73: 271-7.
2. O'Shea, J.J., Pesu, M., Borie, D.C. and Changelian, P.S. A new modality for immunosuppression: Targeting the JAK/STAT pathway. Nat Rev Drug Discov 2004, 3: 555-64.
3. Rawlings, J.S., Rosler, K.M. and Harrison, D.A. The JAK/STAT signaling pathway J Cell Sci 2004, 117: 1281-3.
4. Hombria, J.C. and Brown, S. The fertile field of Drosophila Jak/STAT signalling. Curr Biol 2002, 12: R569-75.
5. Russell, S.M., Taybedi, N., Makajima, H., Riedy, M.C., Roberts, J.L., Aman, M.J., Migone, T.-S., Noguchi, M., Marken, M.L., Buckley, R.H., O'Shea, J.J. and Leonard, W.J. Mutation of Jak3 in a patient with SCID: Essential role of Jak3 in lymphoid development. Science 1995, 270: 797-800.
6. Giordanetto, F. and Kroemer, R.T. Prediction of the structure of human Janus kinase 2 (JAK2) comprising JAK homology domains 1 through 7. Protein Eng 2002, 15: 727-37.
7. Nelson, B.H. and Willerford, D.M. Biology of the interleukin-2 receptor. Adv Immunol 1998,70: 1-81.
8. Duhe, R.J. and Farrar, W.L. Structural and mechanistic aspects of Janus kinases: How the two-faced god wields a double-edged sword. J Interferon Cytokine Res 1998, 18: 1-15.
9. Horvath, C.M. STAT proteins and transcriptional responses to extracellular signals. Trends Biochem Sci 2000, 25: 496-502.
10. Pelligrini, S. and Dusanter-Fourt, I. The structure and function of the Janus kinases (Jaks) and the signal transducers and activators of transcription (STATs). Eur J Biochem 1997, 248: 615-33.
11. Yuan, Z.L., Guan, Y.J., Chatterjee, D. and Chin, Y.E. Stat3 dimerization regulated by reversible acetylation of a single lysine residue. Science 2005, 307: 269-73.
12. Johnston, J.A. Are SOCS suppressors, regulators, and degraders? J Leukoc Biol 2004, 75: 743-8.
13. Alexander, W.S. Suppressors of cytokine signalling (SOCS) in the immune system. Nat Rev Immunol 2002, 2: 410-6.
14. Wang, J. and Campbell, I.L. Cytokine signaling in the brain: Putting a SOCS in it? J Neurosci Res 2002, 67: 423-7.
15. Liu, B., Mink, S., Wong, K.A., Stein, N., Getman, C., Dempsey, P.W., Wu, H. and Shuai, K. PIAS1 selectively inhibits interferon-inducible genes and is important in innate immunity. Nat Immunol 2004, 5: 891-8.
16. Lee, C., Piazza, F., Brutsaert, S., Valens, J., Strehlow, I., Jarosinski, M., Saris, C. and Schindler, C. Characterization of the Stat5 protease. J Biol Chem 1999, 274: 26767-75.
17. Piazza, F., Valens, J., Lagasse, E. and Schindler, C. Myeloid differentiation of FdCP1 cells is dependent on Stat5 processing. Blood 2000, 96: 1358-65.
18. Migone, T.S., Cacalano, N.A., Taylor, N., Yi, T., Waldmann, T.A. and Johnston, J.A. Recruitment of SH2-containing protein tyrosine phosphatase SHP-1 to the interleukin 2 receptor; loss of SHP-1 expression in human T-lymphotropic virus type I-transformed T cells. Proc Natl Acad Sci USA 1998, 95: 3845-50.
19. Jiao, H., Berrada, K., Yang, W., Tabrizi, M., Platanias, L.C. and Yi, T. Direct association with and dephosphorylation of Jak2 kinase by the SH2-domain-containing protein tyrosine phosphatase SHP-1. Mol Cell Biol 1996, 16: 6985-92.
20. Kile, B.T., Nicola, N.A. and Alexander, W.S. Negative regulators of cytokine signaling. Int J Hematol 2001, 73: 292-8.
21. Bousquet, C., Susini, C. and Melmed, S. Inhibitory roles for SHP-1 and SOCS-3 following pituitary proopiomelanocortin induction by leukemia inhibitory factor. J Clin Invest 1999, 104: 1277-85.
22. Kotenko, S.V. and Pestka, S. Jak-Stat signal transduction pathway through the eyes of cytokine class II receptor complexes. Oncogene 2000, 19: 2557-65.
23. O'Shea, J.J., Notarangelo, L.D., Johnston, J.A. and Candotti, F. Advances in the understanding of cytokine signal transduction: The role of Jaks and STATs in immunoregulation and the pathogenesis of immunodeficiency J Clin Immunol 1997, 17: 431-47.
24. O'Shea, J.J., Gadina, M. and Schreiber, R.D. Cytokine signaling in 2002: New surprises in the Jak/Stat pathway. Cell 2002, 109(Suppl): S121-31.
25. Carter-Su, C., Rui, L. and Herrington, J. Role of the tyrosine kinase JAK2 in signal transduction by growth hormone Pediatr Nephrol 2000, 14: 550-7.
26. Vera-Lastra, O., Jara, L.J. and Espinoza, L.R. Prolactin and autoimmunity. Autoimmun Rev 2002, 1: 360-4.
27. Myers, M.G., Jr. Leptin receptor signaling and the regulation of mammalian physiology. Recent Prog Horm Res 2004, 59: 287-304.
28. O'Shea, J.J. Jaks, STATs, cytokine signal transduction, and immunoregulation: Are we there yet? Immunity 1997, 7: 1-11.
29. Wojchowski, D.M., Gregory, R.C., Miller, C.P., Pandit, A.K. and Pircher, T.J. Signal transduction in the erythropoietin receptor system. Exp Cell Res 1999, 253: 143-56.
30. Wendling, F. and Vainchenker, W. Thrombopoietin and its receptor. Eur Cytokine Netw 1998, 9: 221-31.
31. Bain, J., McLauchlan, H., Elliott, M. and Cohen, P. The specificities of protein kinase inhibitors: An update. Biochem J 2003, 371: 199-204.
32. Davies, S., Reddy, H., Caivano, M. and Cohen, P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 2000, 351: 95-105.
33. Macchi, P., Villa, A., Gillani, S., Sacco, M.G., Frattini, A., Porta, F., Ugazio, A.G., Johnston, J.A., Candotti, F. and O'Shea, J.J. Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID). Nature 1995, 377: 65-8.
34. Baird, A.M., Thomas, D.C. and Berg, L.J. T cell development and activation in Jak3 deficient mice. J Leukoc Biol 1998, 63: 669-77.
35. Sohn, S.J., Forbush, K.A., Nguyen, N., Witthuhn, B., Nosaka, T., Ihle, J.N. and Perlmutter, R.M. Requirement for Jak3 in mature T cells: Its role in regulation of T cell homeostasis. J Immunol 1998, 160: 2130-8.
36. O'Shea, J.J., Husa, M., Li, D., Hofmann, S.R., Watford, W., Roberts, J.L., Buckley, R.H., Changelian, P. and Candotti, F. Jak3 and the pathogenesis of severe combined immunodeficiency. Mol Immunol 2004, 41: 727-37.
37. Changelian, P.S., Flanagan, M.E., Ball, D.J. et al. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science 2003, 302: 875-8.
38. Thompson, J., Cubbon, R., Cummings, R., Wicker, L., Frankshun, R., Cunningham, B., Cameron, P., Meinke, P., Liverton, N., Weng, Y. and DeMartino, J. Photochemical preparation of a pyridone containing tetracycle: A JAK protein kinase inhibitor. Bioorg Med Chem Lett 2002, 12: 1219-23.
39. Sudbeck, E., Liu, X., Narla, R.K., Mahajan, S., Ghosh, S., Mao, C. and Uckun, F. Structure-based design of specific inhibitors of Janus kinase 3 as apoptosis-inducing antileukemic agents. Clin Cancer Res 1999, 5: 1569-82.
40. Narla, R.K., Liu, X.P, Klis, D. and Uckun, F.M. Inhibition of human glioblastoma cell adhesion and invasion by 4-(4'-hydroxylphenyl)-amino-6,7- dimethoxyquinazoline (WHI-P131) and 4-(3'-bromo-4'-hydroxylphenyl)-amino-6,7- dimethoxyquinazoline (WHI-P154). Clin Cancer Res 1998, 4: 2463-71.
41. Malavija, R., Chen, C.L., Liu, X.P. and Uckun, F.M. In vivo pharmacokinetics and anti-anaphylactic activity of the novel mast cell inhibitor 4-(4'-hydroxylphenyl)-amino-6,7-dimethoxyquinazoline (WHI-P131). Am J Ther 2001, 8: 35-9.
42. Tibbles, H.E., Vassilev, A., Wendorf, H., Schonhoff, D., Zhu, D., Lorenz, D., Waurzyniak, B., Liu, X.P. and Uckun, F.M. Role of a JAK3-dependent biochemical signaling pathway in platelet activation and aggregation. J Biol Chem 2001, 276: 17815-22.
43. Malaviya, R., Zhu, D., Dibirdik, I. and Uckun, F.M. Targeting Janus kinase 3 in mast cells prevents immediate hypersensitivity reactions and anaphylaxis. J Biol Chem 1999, 274: 27028-38.
44. Kudlacz, E., Perry, B., Sawyer, P. et al. The novel JAK-3 inhibitor CP-690550 is a potent immunosuppressive agent in various murine models. Am J Transplant 2004, 4: 51-7.
45. Conklyn, M., Andresen, C., Changelian, P. and Kudlacz, E. The JAK3 inhibitor CP-690550 selectively reduces NK and CD8+ cell numbers in cynomolgus monkey blood following chronic oral dosing. J Leukoc Biol 2004, 76: 1248-55.
46. Parganas, E., Weng, D., Stravopodis, D., Topham, D.J., Marine, J.-C., Teglund, S., Vanin, E.F., Bodner, S., Colamonici, O.R., Deursen, J.M.V, Grosveld, G. and Ihle, J.N. Jak2 is essential for signaling through a variety of cytokine receptors. Cell 1998, 93: 385-95.
47. Cetkovic-Cvrlje, M., Dragt, A.L., Vassilev, A., Liu, X.P. and Uckun, P.M. Targeting JAK3 with JANEX-1 for prevention of autoimmune type 1 diabetes in NOD mice. Clin Immunol 2003, 106: 213-25.
48. Uckun, F.M., Roers, B.A., Waurzyniak, B., Liu, X.P. and Cetkovic-Cvrlje, M. Janus kinase 3 inhibitor WHI-Pl31/JANEX-1 prevents graft-versus-host disease but spares the graft-versus-leukemia function of the bone marrow allografts in a murine bone marrow transplantation model. Blood 2002, 99: 4192-9.
49. Uckun, F.M., Ek, O., Liu, X.P. and Chen. C.L. In vivo toxicity and pharmacokinetic features of the janus kinase 3 inhibitor WHI-P131 [4-(4'hydroxyphenyl)-amino-6,7-dimethoxyquinazoline. Clin Cancer Res 1999, 5: 2954-62.
50. Stepkowski, S.M., Erwin-Cohen, R.A., Behbod, F., Wang, M.E., Qu, X., Tejpal, N., Nagy, Z.S., Kahan, B.D. and Kirken, R.A. Selective inhibitor of Janus tyrosine kinase 3, PNU156804, prolongs allograft survival and acts synergistically with cyclosporine but additively with rapamycin. Blood 2002, 99: 680-9.
51. Stepkowski, S.M., Nagy, Z.S., Wang, M.E., Behbod, F., Erwin-Cohen, R., Kahan, B.D. and Kirken, R.A. PNU156804 inhibits Jak3 tyrosine kinase and rat heart allograft rejection. Transplant Proc 2001, 33: 3272-3.
52. Mortellaro, A., Songia, S., Gnocchi, P., Ferrari, M., Fornasiero, C., D'Alessio, R., Isetta, A., Colotta, F. and Golay, J. New immunosuppressive drug PNU156804 blocks IL-2-dependent proliferation and NF-kappa B and AP-1 activation. J Immunol 1999, 162: 7102-9.
53. Podder, H., Kahan, B.D. Janus kinase 3: a novel target for selective transplant immunosupression. Expert Opin Ther Targets 2004, 8: 613-29.
54. Platanias, L.C. and Fish, E.N. Signaling pathways activated by interferons. Exp Hematol 1999, 27: 1583-92.
55. Lin, J.-L. and Leonard, W.J. Signaling from the IL-2 receptor to to the nucleus. Cytokine Growth Factor Rev 1997, 8: 313-32.
56. Heinrich, P.C., Behrmann, I., Muller-Newen, G., Schaper, F. and Graeve, L. Interleukin-6-type cytokine signalling through the gpI30/Jak/STAT pathway. Biochem J 1998, 334(Pt 2): 297-314.
57. Rodig, S.J., Meraz, M.A., White, J.M. et al. Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses. Cell 1998, 93: 373-83.
58. Sexl, V., Kovacic, B., Piekorz, R., Moriggl, R., Stoiber, D., Hoffmeyer, A., Liebminger, R., Kudlacek, O., Weisz, E., Rothammer, K. and Ihle, J. Jak1 deficiency leads to enhanced Abelson-induced B-cell tumor deficiency. Blood 2003, 101: 4937-43.
59. Ho, J.M., Nguyen, M.H., Dierov, J.K., Badger, K.M., Beattie, B.K., Tartaro, P., Haq, R., Zanke, B.W., Carroll, M.P. and Barber, D.L. TEL-JAK2 constitutively activates the extracellular signal-regulated kinase (ERK), stress-activated protein/Jun kinase (SAPK/JNK), and p38 signaling pathways. Blood 2002, 100: 1438-48.
60. Carron, C., Cormier, F., Janin, A., Lacronique, V., Giovannini, M., Daniel, M.T., Bernard, O. and Ghysdael, J. TEL-JAK2 transgenic mice develop T-cell leukemia. Blood 2000, 95: 3891-9.
61. Lacronique, V., Boureux, A., Valle, V.D., Poirel, H., Quang, C.T., Mauchauffe, M., Berthou, C., Lessard, M., Berger, R., Ghysdael, J. and Bernard, O.A. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science 1997, 278: 1309-12.
62. Meydan, N., Grunberger, T., Dadi, H., Shahar, M., Arpala, E., Lapidot, Z., Leeder, J., Freedman, M., Cohen, A., Gazit, A., Levitzki, A. and Roifman, C. Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature 1996, 379: 645-8.
63. Miyamoto, N., Sugita, K., Goi, K., Inukai, T., Lijima, K., Tezuka, T., Kojika, S., Nakamura, M., Kagami, K. and Nakazawa, S. The JAK2 inhibitor AG490 predominantly abrogates the growth of human B-precursor leukemic cells with Ilq23 translocation or Philadelphia chromosome. Leukemia 2001, 15: 1758-68.
64. Flowers, L.O., Johnson, H.M., Mujtaba, M.G., Ellis, M.R., Haider, S.M. and Subramaniam, P.S. Characterization of a peptide inhibitor of Janus kinase 2 that mimics suppressor of cytokine signaling 1 function. J Immunol 2004, 172: 7510-8.
65. Pellegrini, S. and Dusanter-Fourt, I. The structure, regulation and function of the Janus kinases (JAKs) and the signal transducers and activators of transcription (STATs). Eur J Biochem 1997, 248: 615-33.
66. Stoiber, D., Kovacic, B., Schuster, C., Schellack, C., Karaghiosoff, M., Kreibich, R., Weisz, E., Artwohl, M., Kleine, O.C., Muller, M., Baumgartner-Parzer, S., Ghysdael, J., Freissmuth, M. and Sexl, V. TYK2 is a key regulator of the surveillance of B lymphoid tumors J Clin Invest 2004, 114: 1650-8.
67. Olyaei, J., deMattos A. and Bennett, W. Nephrotoxicity in immunosuppressive drugs: New insight and preventive strategies. Cur Opin Crit Care 2001, 7: 384-9.
68. Druker, B. STI571(Gleevec) as a paradigm for cancer therapy. Trends Mol Med 2002, 8: S14-8.
69. Boggon, T.J., Li, Y., Manley, P.W. and Eck, M.J. Crystal structure of the JAK3 kinase domain in complex with a staurosporine analogue. Blood 2005: preprint available online.
70. Levine, R.L., Wadleigh, M., Cools, J. et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosas. Cancer Cell 2005, 7: 387-97.